Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma

This study is testing a three-drug combination — belantamab mafodotin, pomalidomide, and dexamethasone — for people with high-risk multiple myeloma who have recently had a stem cell transplant. High-risk myeloma has specific genetic features that make it more likely to return or be aggressive. **You may be eligible if...** - You have multiple myeloma with high-risk genetic features (specific chromosomal changes like del(17p), t(4;14), t(14;16), t(14;20), or plasma cell leukemia) - You received an autologous stem cell transplant within the past year and achieved at least a partial response - You are being enrolled 60–100 days after your transplant - You are 18 years old or older - Your blood counts and organ function meet the required levels **You may NOT be eligible if...** - You have corneal eye disease, active liver disease, or active kidney infection - You wear contact lenses (you must stop wearing them during the study) - You are currently enrolled in another clinical trial - You have had recent heart problems or uncontrolled high blood pressure - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.